Frailty in advanced heart failure: A consequence of aging or a separate entity?

Clinical Medicine Insights: Cardiology

Volumn 9, Issue , 2015, Pages 39-46

  Goldwater, Deena S ^a   Pinney, Sean P ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Frailty; Geriatric cardiology; Heart failure; Sarcopenia

Indexed keywords

AGING; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXERCISE; FRAIL ELDERLY; FRAILTY; HEART FAILURE; HUMAN; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUSCLE MASS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PHYSICAL ACTIVITY; PHYSICAL DISEASE; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT RESPONSE;

EID: 84937434188     PISSN: None     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S19698     Document Type: Article

References (90)

1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011; 8(1): 30-41.
2. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012; 60(8): 1487-92.
3. Park SK, Richardson CR, Holleman RG, Larson JL. Frailty in people with COPD, using the National Health and Nutrition Evaluation Survey dataset (2003-2006). Heart Lung. 2013; 42(3): 163-70.
4. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014; 63(8): 747-62.
5. McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J Am Geriatr Soc. 2013; 61(6): 896-901.
6. Kirklin JK, Naftel DC, Pagani FD, et al. Sixth INTERMACS annual report: a 10, 000-patient database. J Heart Lung Transplant. 2014; 33(6): 555-64.
7. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010; 39: 412-23.
8. Short KR, Vittone JL, Bigelow ML, Proctor DN, Nair KS. Age and aerobic exercise training effects on whole body and muscle protein metabolism. Am J Physiol Endocrinol Metab. 2004; 286(1): E92-101.
9. Fried LP, Tangen CM, Walston J, et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3): M146-56.
10. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011; 27(1): 79-87.
11. Hubbard RE, O'Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009; 13(9B): 3103-9.
12. Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009; 22(3): 819-27.
13. Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006; 119(6):. e9-17.
14. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002; 57(5): M326-32.
15. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004; 59(3): 242-8.
16. Kalyani RR, Varadhan R, Weiss CO, Fried LP, Cappola AR. Frailty status and altered glucose-insulin dynamics. J Gerontol A Biol Sci Med Sci. 2012; 67(12): 1300-6.
17. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014; 2(10): 819-29.
18. Johar H, Emeny RT, Bidlingmaier M, et al. Blunted diurnal cortisol pattern is associated with frailty: a cross-sectional study of 745 participants aged 65 to 90 years. J Clin Endocrinol Metab. 2014; 99(3): E464-8.
19. O'Connell MDL, Tajar A, Roberts SA, Wu FCW. Do androgens play any role in the physical frailty of ageing men? Int J Androl. 2011; 34(3): 195-211.
20. Semba RD, Ferrucci L, Sun K, et al. Oxidative stress and severe walking disability among older women. Am J Med. 2007; 120(12): 1084-9.
21. Lexell J. Human aging, muscle mass, and fiber type composition. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 1995; 50: 11-6.
22. Larsson L. Histochemical characteristics of human skeletal muscle during aging. Acta Physiol Scand. 1983; 117(3): 469-71.
23. Nilwik R, Snijders T, Leenders M, et al. The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. Exp Gerontol. 2013; 48(5): 492-8.
24. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol. 2013; 45(10): 2191-9.
25. Pugh TD, Conklin MW, Evans TD, et al. A shift in energy metabolism anticipates the onset of sarcopenia in rhesus monkeys. Aging Cell. 2013; 12(4): 672-81.
26. López-Armada MJ, Riveiro-Naveira RR, Vaamonde-García C, Valcárcel-Ares MN. Mitochondrial dysfunction and the inflammatory response. Mitochondrion. 2013; 13(2): 106-18.
27. Rogers MA, Hagberg JM, Martin WH, Ehsani AA, Holloszy JO. Decline in VO2 max with aging in master athletes and sedentary men. J Appl Physiol. 1990; 68(5): 2195-9.
28. Toth MJ, Gardner AW, Ades PA, Poehlman ET. Contribution of body composition and physical activity to age-related decline in peak VO2 in men and women. J Appl Physiol. 1994; 77(2): 647-52.
29. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147(8): 755-63.
30. de Oliveira RJ, Bottaro M, Motta AM, et al. Association between sarcopenia-related phenotypes and aerobic capacity indexes of older women. J Sports Sci Med. 2009; 8(3): 337-43.
31. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA. 1990; 263(22): 3029-34.
32. Mangione KK, Miller AH, Naughton IV. Cochrane review: improving physical function and performance with progressive resistance strength training in older adults. Phys Ther. 2010; 90(12): 1711-5.
33. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD002759.
34. Keysor JJ, Jette AM. Have we oversold the benefit of late-life exercise? J Gerontol A Biol Sci Med Sci. 2001; 56(7): M412-23.
35. Wolf SL, Sattin RW, Kutner M, O'Grady M, Greenspan AI, Gregor RJ. Intense tai chi exercise training and fall occurrences in older, transitionally frail adults: a randomized, controlled trial. J Am Geriatr Soc. 2003; 51(12): 1693-701.
36. Wolf SL, O'Grady M, Easley KA, Guo Y, Kressig RW, Kutner M. The influence of intense Tai Chi training on physical performance and hemodynamic outcomes in transitionally frail, older adults. J Gerontol A Biol Sci Med Sci. 2006; 61(2): 184-9.
37. Faber MJ, Bosscher RJ, Chin A, Paw MJ, van Wieringen PC. Effects of exercise programs on falls and mobility in frail and pre-frail older adults: a multicenter randomized controlled trial. Arch Phys Med Rehabil. 2006; 87(7): 885-96.
38. Binder EF, Schechtman KB, Ehsani AA, et al. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc. 2002; 50(12): 1921-8.
39. Burton LA, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging. 2010; 2010(5): 217-28.
40. Sukhanov S, Semprun-Prieto L, Yoshida T, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci. 2011; 342(2): 143-7.
41. Witham MD, Sumukadas D, McMurdo MET. ACE inhibitors for sarcopenia-as good as exercise training? Age Ageing. 2008; 37(4): 363-5.
42. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002; 359(9310): 926-30.
43. Haehling von S, Steinbeck L, Doehner W, Springer J, Anker SD. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol. 2013; 45(10): 2257-65.
44. Burton LA, Sumukadas D, Witham MD, Struthers AD, McMurdo MET. Effect of spironolactone on physical performance in older people with self-reported physical disability. Am J Med. 2013; 126(7): 590-7.
45. Sumukadas D, Band M, Miller S, et al. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2014; 69(6): 736-43.
46. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr. 2008; 27(6): 793-9.
47. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013; 34(7): 512-9.
48. Haykowsky MJ, Timmons MP, Kruger C, McNeely M, Taylor DA, Clark AM. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013; 111(10): 1466-9.
49. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349(9058): 1050-3.
50. Lupón J, González B, Santaeugenia S, et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Rev Esp Cardiol. 2008; 61(8): 835-42.
51. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999; 20(9): 683-93.
52. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323(4): 236-41.
53. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 1991; 66(5): 356-8.
54. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997; 30(4): 997-1001.
55. Haehling von S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007; 73(2): 298-309.
56. Khan H, Kalogeropoulos AP, Georgiopoulou VV, et al. Frailty and risk for heart failure in older adults: the health, aging, and body composition study. Am Heart J. 2013; 166(5): 887-94.
57. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 97(14): 1382-91.
58. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001; 104(7): 826-31.
59. Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation. 1989; 80(5): 1338-46.
60. Borina E, Pellegrino MA, D'Antona G, Bottinelli R. Myosin and actin content of human skeletal muscle fibers following 35 days bed rest. Scand J Med Sci Sports. 2010; 20(1): 65-73.
61. Caiozzo VJ, Baker MJ, Herrick RE, Tao M, Baldwin KM. Effect of spaceflight on skeletal muscle: mechanical properties and myosin isoform content of a slow muscle. J Appl Physiol. 1994; 76(4): 1764-73.
62. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. 1990; 81(2): 518-27.
63. Tikunov B, Levine S, Mancini D. Chronic congestive heart failure elicits adaptations of endurance exercise in diaphragmatic muscle. Circulation. 1997; 95(4): 910-6.
64. Francis DP, Shamim W, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J. 2000; 21(2): 154-61.
65. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997; 30(7): 1758-64.
66. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999; 33(4): 959-65.
67. Filippatos GS, Kanatselos C, Manolatos DD, et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. Int J Cardiol. 2003; 90(1): 107-13.
68. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011; 301(6): H2181-90.
69. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail. 2010; 3(4): 537-46.
70. Rosca MG, Hoppel CL. Mitochondrial dysfunction in heart failure. Heart Fail Rev. 2013; 18(5): 607-22.
71. Piepoli MF, Davos C, Francis DP, Coats AJS. ExTraMATCH collaborative. exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004; 328(7433): 189.
72. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010; 12(7): 706-15.
73. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014; 4: CD003331.
74. O'Connor CM, Whellan DJ, Lee KL, et al; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301(14): 1439-50.
75. Flynn KE, Piña IL, Whellan DJ, et al; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301(14): 1451-9.
76. Blumenthal JA, Babyak MA, O'Connor C, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA. 2012; 308(5): 465-74.
77. Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging Catabolism Study. Circulation. 2012; 125(22): 2716-27.
78. Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002; 39(4): 653-63.
79. Conraads VM, Beckers P, Bosmans J, et al. Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease. Eur Heart J. 2002; 23(23): 1854-60.
80. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003; 107(25): 3133-40.
81. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109(13): 1594-602.
82. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013; 62(16): e147-239.
83. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev. 2008; 88(2): 729-67.
84. Scherer M, Düngen HD, Inkrot S, et al. Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). Eur J Intern Med. 2013; 24(4): 333-8.
85. Dössegger L, Aldor E, Baird MG, et al. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre, double-blind, placebo-controlled trial. Eur Heart J. 1993; 14(suppl C): 18-23.
86. Lund LH, Freda P, Williams JJ, LaManca JJ, LeJemtel TH, Mancini DM. Growth hormone resistance in severe heart failure resolves after cardiac transplantation. Eur J Heart Fail. 2009; 11(5): 525-8.
87. Habedank D, Ewert R, Hummel M, Wensel R, Hetzer R, Anker SD. Changes in exercise capacity, ventilation, and body weight following heart transplantation. Eur J Heart Fail. 2007; 9(3): 310-6.
88. Baker AM, Levine TB, Goldberg AD, Levine AB. Natural history and predictors of obesity after orthotopic heart transplantation. J Heart Lung Transplant. 1992; 11(6): 1156-9.
89. Williams JJ, Lund LH, LaManca J, et al. Excessive weight gain in cardiac transplant recipients. J Heart Lung Transplant. 2006; 25(1): 36-41.
90. Khawaja T, Chokshi A, Ji R, et al. Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure. J Cachexia Sarcopenia Muscle. 2014; 5(4): 297-305.